12.11.2015

ARS CRO initiated regulatory approval of two BE/PK studies of Nilotinib and Lenalidomide sponsored by the EU GMP certified Russian pharmaceutical company specialized in endocrinology, oncology, pulmonology, gynecology, and other areas.